Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Candel Therapeutics Inc
(NQ:
CADL
)
5.330
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Candel Therapeutics Inc
< Previous
1
2
Next >
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
November 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
October 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
October 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 18, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Join Russell 3000® Index
June 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
June 03, 2024
By Jeremy Golden, Benzinga
Via
TheNewswire.com
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
May 30, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
May 23, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
May 22, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
May 20, 2024
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
April 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
April 09, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Unusually High Volume Points to Upside in These Stocks
April 05, 2024
Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.
Via
MarketBeat
Topics
ETFs
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
April 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
March 06, 2024
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
Via
FinancialNewsMedia
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
March 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
February 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
February 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
December 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
November 28, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 09, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
November 04, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
November 03, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
October 18, 2023
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.